| | |
Treatment group
|
p
|
|---|
| |
EFV only
| |
EFV + RIF
|
|---|
|
N
|
Median (IQR)
|
N
|
Median (IQR)
|
|---|
|
Day-3
|
57
|
2.48 (1.85-2.92)
|
107
|
1.85 (1.34-2.86)
|
0.02
|
|
week-1
|
53
|
2.37 (1.92-3.18)
|
57
|
1.80 (1.34-2.49)
|
0.01
|
|
week-2
|
53
|
2.21 (1.63-3.21)
|
100
|
1.94 (1.38-2.60)
|
0.21
|
|
week-4
|
49
|
2.45 (1.73-3.22)
|
103
|
1.87 (1.43-3.13)
|
0.48
|
|
week-6
|
38
|
2.37 (1.70-3.51)
|
86
|
1.89 (1.63-4.19)
|
0.93
|
|
week-8
|
50
|
2.41 (1.64-3.06)
|
118
|
1.82 (1.42-3.21)
|
0.40
|
|
week-12
|
44
|
2.41 (1.65-3.55)
|
101
|
2.04 (1.47-3.64)
|
0.69
|
- Plasma efavirenz concentrations were monitored at day 3 and at 1, 2, 4, 6, 7, 8 and 12 weeks after starting efavirenz based HAART. For statistical analysis, Log transformed efavirenz concentration was used using independent sample T-test.
